Valuation : Tenax Therapeutics, Inc.

Market Cap 10Cr 8.77Cr 8.23Cr 7.53Cr 14Cr 963.85Cr 14Cr 97Cr 38Cr 492.57Cr 38Cr 37Cr 1.59TCr P/E 2026 *
-1.23x
P/E 2027 * -1.19x
Enterprise Value 1.68Cr 1.44Cr 1.35Cr 1.24Cr 2.31Cr 158.45Cr 2.33Cr 16Cr 6.23Cr 81Cr 6.29Cr 6.16Cr 260.79Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Tenax Therapeutics, Inc.

1 day+3.93%
1 week-14.32%
Current month-0.82%
1 month-86.79%
3 months-83.54%
6 months-84.73%
Current year-85.03%
1 week 1.73
Extreme 1.7301
2.11
1 month 1.31
Extreme 1.31
14.25
Current year 1.31
Extreme 1.31
19.4
1 year 1.31
Extreme 1.31
19.4
3 years 1.31
Extreme 1.31
61.2
5 years 1.31
Extreme 1.31
3,135.04
10 years 1.31
Extreme 1.31
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26
Adar1 Capital Management LLC
BuyCompany 1,87,704 0.5016%
24/08/26
Adar1 Capital Management LLC
BuyCompany 1,07,374 0.2869%
20/08/26
Adar1 Capital Management LLC
OtherCompany 39,18,120 10.4696%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%-14.32%-69.58%-93.04% 10Cr
-2.68%-2.57%-1.63%+14.84% 5.03TCr
-0.98%+0.13%+434.42%+517.85% 4.52TCr
-1.79%+1.73%+44.66%+20.55% 4.47TCr
-0.74%-2.17%+12.56%+75.14% 4.12TCr
+0.53%-1.67%+15.16%+49.88% 3.31TCr
-1.09%+7.45% - - 1.78TCr
-0.05%-1.33%+22.87%+123.56% 1.66TCr
-0.74%+0.77%+16.15%+28.34% 1.48TCr
-1.21%-0.72%+78.30%+41.66% 1.4TCr
Average -0.53%-1.86%+61.44%+86.53% 2.78TCr
Weighted average by Cap. -1.21%-0.47%+93.35%+126.36%

Financials

2026 *2027 *
Net sales - -
Net income -7.27Cr -6.26Cr -5.87Cr -5.37Cr -10Cr -687.56Cr -10Cr -69Cr -27Cr -351.37Cr -27Cr -27Cr -1.13TCr -8.41Cr -7.23Cr -6.79Cr -6.21Cr -12Cr -794.64Cr -12Cr -80Cr -31Cr -406.09Cr -32Cr -31Cr -1.31TCr
Net Debt -8.52Cr -7.33Cr -6.88Cr -6.29Cr -12Cr -805.4Cr -12Cr -81Cr -32Cr -411.59Cr -32Cr -31Cr -1.33TCr -1.02Cr -87.76L -82.36L -75.35L -1.41Cr -96Cr -1.42Cr -9.74Cr -3.79Cr -49Cr -3.83Cr -3.75Cr -158.7Cr
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
04/26/04 $1.825 +2.53% 10,43,199
03/26/03 $1.780 -3.78% 1,40,92,406
02/26/02 $1.850 +2.78% 37,02,049
01/26/01 $1.800 -2.17% 42,98,483
31/26/31 $1.840 -13.62% 1,72,37,411
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.780USD
Average target price
12.56USD
Spread / Average Target
+605.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock